Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.

Abstract: A method for separating and purifying the active hematinic species (AHS) present in iron-saccharidic compositions, including AHS such as sodium ferric gluconate complex, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function. The method separates the AHS from one or more excipients and, preferably, lyophilizes the separated AHS. Separation of the AHS permits its analytical quantification, further concentration, purification and/or lyophilization as well as preparation of new and useful products and pharmaceutical compositions, including those useful for the treatment of humans and animals.

Abstract: The invention relates to the use of an adsorbent and a sealed package, for example an overwrap, to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.

Abstract: Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.

Abstract: An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and/or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sjögren syndrome.

Abstract: The systems and methods of the present disclosure, in a broad aspect, provide for treatment of cardiac tissue via localized delivery of PARP inhibitors. These systems include a composition comprising at least one poly(ADP-ribose) polymerase (PARP) inhibitor; and at least one delivery device for introducing the composition into the cardiac tissue.

Abstract: Compounds of the formula: and compositions containing one or more such compounds, the compositions preferably being suitable for topical application to the skin.

Abstract: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.

Abstract: The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosamino-glycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth fact is IFG-1.

Abstract: Techniques for lung injury treatment are provided. For example, a technique for treating a lung injury in a patient includes the step of administering a therapeutically effective amount of a sophorolipid to the patient.

Abstract: A method of controlling growth and/or controlling or preventing pathogenic damage or pest damage in a plant propagation material, a plant, parts of a plant and/or plant organs that grow at a later point in time, which comprises applying on the plant, part of the plant, or surroundings thereof, a pesticidal combination comprising, for example, at least two active ingredient components optionally together with one or more customary formulation auxiliaries, wherein component (I) is one or more of a pesticide and component (II) is isoflavone (formononetin.genistein or mixtures thereof) in any desired sequence or simultaneously.

Abstract: The invention relates to pesticidal mixtures comprising as active compounds 1) at least one cyanosulfoximine compound I of the formula (I) wherein R1, R2 and G are defined in the description; and 2) at least one active compound II selected from a group A comprising acteylcholine esterase inhibitors, GABA-gated chloride channel antagonists, sodium channel modulators, nicotinic acetylcholine receptor agonists/antagonists, chloride channel activators, juvenile hormone mimics, compounds affecting the oxidative phosphorylation, inhibitors of the chitin biosynthesis, moulting disruptors, inhibitors of the MET, voltage-dependent sodium channel blockers, inhibitors of the lipid synthesis and other compounds as defined in the description, in synergistically gistically effective amounts. The invention relates further to methods and use of these mixtures for combating insects, arachnids or nematodes in and on plants, and for protecting such plants being infested with pests and also for protecting seeds.

Abstract: The present invention provides a fucoidan-derived low molecular weight compound with a good quality of taste, which has a specified structure and function and is free from problems in absorption, antigenicity, uniformity, an anticoagulant activity and so on, which problems arise when developing fucoidan, a sulfated polysaccharide having an extremely large molecular weight, as drugs or health foods. As a result of analyzing low molecular weight compounds obtained by acid hydrolysis of fucoidan, the inventors have identified fucoidan oligosaccharides (I) to (XI). Further, these oligosaccharides have been found to have anti-obesity and/or blood glucose elevation suppressing effects through inhibition of carbohydrate and/or lipid absorption as a result of ?-glucosidase inhibition and/or lipase inhibition.

Abstract: The present invention provides a novel therapeutic or preventive method, a pharmaceutical composition and use thereof, that exhibit superior anti-obesity effects (body weight-reducing (losing) effects and/or body fat mass-reducing effects). Specifically, the present invention provides a pharmaceutical composition comprising the combination of a dipeptidyl peptidase 4 inhibitor and a sweetener having a GLP-1 secretion-stimulating action, as well as use thereof for the manufacture of a medicament. The present invention also provides a method for treating or preventing obesity, comprising administering an effective amount of (a) a dipeptidyl peptidase 4 inhibitor and (b) a sweetener having a GLP-1 secretion-stimulating action to a patient suffering from symptoms of obesity.

Abstract: Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine.

Abstract: An immunogenic composition, and method of using the composition to elicit an immune response to Campylobacter jejuni. The composition is an isolated polysaccharide polymer composed of one or more forms of disaccharide polymers.

Abstract: A method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula I,

Abstract: The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.

Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.

Abstract: A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile solvent system, and spray drying the system thus formed to provide porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof.

Abstract: The present invention relates to a food compound comprising an emulsion containing triglyceride oils as well as a low-glycemic saccharose isomer.

Abstract: Specific inhibitors of hyaluronidase (HYA1-type hyaluronidase) are used to treat cancer, especially carcinoma and solid tumors, and/or precancerous conditions.

Abstract: The present invention relates to percarboxylated polysaccharide selected from the group consisting of gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivatives; the process for their preparation and their use in the pharmaceutical, biomedical, surgical and healthcare fields.

Abstract: A process is provided for preparing an iron sucrose complex, substantially free of excipients, for providing an iron sucrose complex co-precipitated with sucrose, and for providing iron sucrose complexes in aqueous solution.

Abstract: A composition having a pH in the range of from 3 to 8.5, comprising: (a) in the range of from 0.1% to <10% w/w (based on the total weight of the composition) of a stock solution comprising a mixture of bioflavonoids and fruit acids or salts thereof; (b) sodium hyaluronate; and (c) water; and, optionally, (d) a pharmaceutically acceptable carrier therefor; wherein the sodium hyaluronate has an average molecular weight of between 800,000 and 4,000,000.

Abstract: Pesticidal mixtures comprising aminothiazoline compounds The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one aminothiazoline compound I of the Formula (I) wherein R1, R2, R3, R4, R5 and R6 are defined in the description; and 2) at least one active compound II selected from a group A comprising acetylcholine esterase inhibitors, GABA-gated chloride channel antagonists, sodium channel modulators, nicotinic acetylcholine receptor agonists/antagonists, chloride channel activators, juvenile hormone mimics, compounds affecting the oxidative phosphorylation, inhibitors of the chitin biosynthesis, moulting disruptors, inhibitors of the MET, voltage-dependent sodium channelblockers, inhibitors of the lipidsynthesis and other compounds as defined in the description, in synergistically effective amounts.

Abstract: Provided are cosmetic preparations for topical application containing nanocrystals of cosmetic actives leading to an increased bioactivity of the molecules in the skin and methods of making the cosmetic preparations. The nanocrystals can be added to any cosmetic topical formulation, e. g. creams, lotions and liposomal dispersions. The drug nanocrystals are produced by a combination process of low energy pearl milling followed by a high energy high-pressure homogenization leading to nanocrystal suspensions (nanosuspensions) of improved physical stability.

Abstract: Solid pharmaceutical compositions for parenteral injection comprising a binder and at least one therapeutic agent. The pharmaceutical composition has the strength to be injected directly with the need of using cannulas or the like.

Abstract: Dry powders of amino acids which exhibit great oral meltability and solubility, may be produced by spray drying a hydrous liquid of amino acids to produce a powder of amino acids, where the hydrous liquid of amino acids is prepared into the form of microfine liquid droplets in the presence of trehalose for spray drying, to obtain a powder having a mean particle size of 0.1 ?m to 15 ?m, as well as granulating and drying during the spray drying or after the spray drying, to obtain a granulated powder having a mean particle size of 20 ?m to 1,000 ?m.

Abstract: A method of protecting tissue from trauma during a surgical procedure, the method comprising the step of coating at least a portion of the tissue with a viscoelastic composition comprising: a mixture of hyaluronic acid and/or salts thereof and hydroxypropyl methylcellulose, wherein the concentration of hyaluronic acid and/or salts thereof is a minimum of about 0.1% w/v and a maximum of about 6% w/v and the concentration of hydroxypropyl methylcellulose is a minimum of about 0.05% w/v and a maximum of about 5% w/v, based upon the total volume of the viscoelastic composition; tris[hydroxymethyl]aminomethane at a maximum of about 50 mM and a minimum of about 0.1 mM based upon the total weight of the viscoelastic composition; and a hexahydric alcohol.

Abstract: An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.

Abstract: The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety profile. The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.

Abstract: The invention relates to a process for the surface-energy passivation of lactose which is intended for use as an excipient in the production of inhalable powders, and the use of such optimised carrier materials in the manufacture of inhalable powders.

Abstract: The present invention includes a method of treating inflammation of the eye comprising administering to an eye of a patient suffering from inflammation of the eye, a composition comprising an aqueous solution of alginate having a minimum of about 50% mannuronate residues based upon the total number of saccharide monomeric units.

Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.

Abstract: A nutritional supplement comprises about 2 parts roasted, ground flaxseed, about 2 parts of chick pea flour, about 1.5-2 parts of whole wheat or brown rice flour, about 1 part of raw, ground almonds and optionally, about 0.5-1 part of whole wheat bran. The supplement may additionally contain one or both of raw blue agave nectar and sunflower oil. The supplement may also contain cardamom and/or ginger. The nutritional supplement comprises at least about 1.5 grams of Omega-3 fatty acids, less than about 1.5 grams (g) of glucose, and less than about 0.6 g of sucrose in a serving of about 2 ounces (about 59 ml). A method of supplementing the nutrition of an individual comprises administering the nutritional supplement to the individual.

Abstract: This invention generally refers to the process to obtain a compound and a standard pharmaceutical product from one or more parts of plant of the Stachytarpheta (Verhenaceae family) species, as well as roots, stems, barks, and leaves of plants in the form of extracts or enriched fractions, or pure isolated compounds or compounds obtained from synthesis, used alone or mixed with other natural or synthetic products, in different ratios, in order to integrate pharmaceutical compositions to be used by appropriate routes (topic or oral), particularly in the form of tablets, capsules, dyes, emulsions, W/O and O/W (creams and gels), liposomes, microcapsules, nanoparticles, aerosols, ointments, and the like, as well as formulations for slow-release implants, used to treat vitiligo.

Abstract: The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals, such as livestock.

Abstract: A composition, method of preparation1 and use to enhance the cosmetic feel of oil-in-water emulsions based upon the addition to the oil in water emulsion of one or more alkylpolyxylosides represented by formula: R—O—(X)p, wherein p is a decimal number between 1 and 5, wherein X is a xylose residue, and wherein R is a branched alkyl radical represented by the formula: CH(CnH2n+1)(CmH2m+1)—CH2— wherein m is an integer between 6 and 12, n is an integer between 8 and 16, and the sum of m+n is in the range of from about 14 to 26.

Abstract: A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The invention relates to the use of isomaltulose or mixtures of isomaltulose for the production of functional food products for improving the regeneration of individuals exposed to physical exertion.

Abstract: The present invention provides compounds and methods for treatment of viral diseases and cancer.

Abstract: The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.

Abstract: Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.

Abstract: A topical drying composition is providing containing trehalose as the effective moisture (sweat) removing ingredient. The composition may be used in aqueous form or preferably as a cream and in addition to trehalose it contains several ingredients such as sorbitan monolaurate, polysorbitan, a moisturizer, a thickener, a softener, an antibacterial agent and a pH adjusting component to adjust the pH of the composition between about 5.5 to about 7.5. Sterilized water is used as the carrier for the composition. The topical composition can be applied to the area which is vulnerable to sweating after vigorous exercise in order to moisturize sweating on the skin.

Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.

Abstract: Method of preparing a non-hygroscopic pulverulent composition, includes a step for the spray drying, without an atomization support, of an aqueous solution containing at least one initially hygroscopic product, having a glass transition temperature ranging from 10° C. to 110° C., and a cryogenic fluid, especially a food-grade cryogenic fluid, or a mixture of cryogenic fluids, particularly chosen from liquid air, nitrogen and carbon dioxide, the aqueous solution being obtained by dissolving the cryogenic fluid in an initial aqueous solution containing the initially hygroscopic product.

Abstract: The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.

Abstract: Disclosed are genes that, when overexpressed in cells expressing alpha-synuclein, either suppress or enhance alpha-synuclein mediated cellular toxicity. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.

Abstract: The invention relates to the use of prebiotics for the preparation of food or pharmaceutical compositions which are intended for the treatment and/or prevention of hyperglycaemic syndromes and, in particular, for the treatment of Type II diabetes and/or the prevention of the onset of Type II diabetes in patients with a predisposition to developing the type of diabetes. The invention also relates to the food and pharmaceutical compositions containing the prebiotics.